Healthcare provider profile · identity verified

Mark Lucey

Internal Medicine · PHILADELPHIA, PA · NPI 1780115329

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	362	116
Amlodipine Besylate	Amlodipine Besylate	320	91
Omeprazole	Omeprazole	282	92
Lisinopril	Lisinopril	252	72
Rosuvastatin Calcium	Rosuvastatin Calcium	252	79
Levothyroxine Sodium	Levothyroxine Sodium	225	56
Losartan Potassium	Losartan Potassium	197	63
Metoprolol Succinate	Metoprolol Succinate	190	69
Albuterol Sulfate Hfa	Albuterol Sulfate	171	70
Metformin Hcl	Metformin Hcl	160	49
Hydrochlorothiazide	Hydrochlorothiazide	154	47
Valsartan	Valsartan	138	46
Eliquis	Apixaban	132	36
Gabapentin	Gabapentin	132	45
Metformin Hcl Er	Metformin Hcl	125	42
Pantoprazole Sodium	Pantoprazole Sodium	117	39
Prednisone	Prednisone	111	68
Sertraline Hcl	Sertraline Hcl	99	34
Famotidine	Famotidine	86	37
Mounjaro	Tirzepatide	85	21
Furosemide	Furosemide	83	27
Oxycodone Hcl	Oxycodone Hcl	82	24
Ezetimibe	Ezetimibe	79	21
Fluticasone Propionate	Fluticasone Propionate	76	40
Jardiance	Empagliflozin	76	24
Spironolactone	Spironolactone	76	20
Allopurinol	Allopurinol	74	22
Trazodone Hcl	Trazodone Hcl	69	28
Diclofenac Sodium	Diclofenac Sodium	67	24
Farxiga	Dapagliflozin Propanediol	65	17
Tamsulosin Hcl	Tamsulosin Hcl	62	22
Carvedilol	Carvedilol	59	16
Tramadol Hcl	Tramadol Hcl	59	25
Lorazepam	Lorazepam	58	17
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	57	22
Pregabalin	Pregabalin	56	18
Rybelsus	Semaglutide	56	12
Alendronate Sodium	Alendronate Sodium	54	19
Metoprolol Tartrate	Metoprolol Tartrate	54	17
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	54	19
Doxycycline Hyclate	Doxycycline Hyclate	53	47
Escitalopram Oxalate	Escitalopram Oxalate	53	17
Glipizide Er	Glipizide	53	14
Citalopram Hbr	Citalopram Hydrobromide	52	19
Potassium Chloride	Potassium Chloride	51	14
Breo Ellipta	Fluticasone/Vilanterol	48	suppressed
Cefdinir	Cefdinir	48	42
Simvastatin	Simvastatin	48	17
Finasteride	Finasteride	45	11
Clonazepam	Clonazepam	43	18
Donepezil Hcl	Donepezil Hcl	42	18
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	42	12
Atenolol	Atenolol	41	13
Baclofen	Baclofen	41	14
Pravastatin Sodium	Pravastatin Sodium	39	14
Duloxetine Hcl	Duloxetine Hcl	37	14
Meloxicam	Meloxicam	37	19
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	36	11
Ozempic	Semaglutide	36	11
Torsemide	Torsemide	35	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	32	30
Januvia	Sitagliptin Phosphate	32	suppressed
Alprazolam	Alprazolam	31	12
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	31	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Montelukast Sodium	Montelukast Sodium	31	suppressed
Glimepiride	Glimepiride	30	12
Irbesartan	Irbesartan	29	suppressed
Clopidogrel	Clopidogrel Bisulfate	28	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	28	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	27	22
Labetalol Hcl	Labetalol Hcl	26	suppressed
Memantine Hcl	Memantine Hcl	25	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	24	suppressed
Ciclopirox	Ciclopirox Olamine	23	15
Terazosin Hcl	Terazosin Hcl	23	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	23	14
Buspirone Hcl	Buspirone Hcl	22	suppressed
Ibuprofen	Ibuprofen	21	suppressed
Amoxicillin	Amoxicillin	20	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	20	suppressed
Ketoconazole	Ketoconazole	20	14
Methotrexate	Methotrexate Sodium	20	suppressed
Midodrine Hcl	Midodrine Hcl	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Tresiba Flextouch U-100	Insulin Degludec	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Sucralfate	Sucralfate	19	suppressed
Tresiba Flextouch U-200	Insulin Degludec	19	suppressed
Glipizide	Glipizide	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Trospium Chloride	Trospium Chloride	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Bumetanide	Bumetanide	17	suppressed
Colchicine	Colchicine	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	17	suppressed
Fluconazole	Fluconazole	16	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Nexletol	Bempedoic Acid	15	suppressed
Oxycontin	Oxycodone Hcl	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Aripiprazole	Aripiprazole	14	suppressed
Celecoxib	Celecoxib	14	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	14	suppressed
Folic Acid	Folic Acid	14	suppressed
Isosorbide Mononitrate	Isosorbide Mononitrate	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	12
Nifedipine Er	Nifedipine	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Trintellix	Vortioxetine Hydrobromide	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	11
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Zenpep	Lipase/Protease/Amylase	13	suppressed
Austedo Xr	Deutetrabenazine	12	suppressed
Cefaclor	Cefaclor	12	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	12	suppressed
Linzess	Linaclotide	11	suppressed
Premarin	Estrogens, Conjugated	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error